Board Change • May 22
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • May 01
Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026 Genix Pharmaceuticals Corporation, Annual General Meeting, Jul 08, 2026. Board Change • Mar 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 05
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 23
Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 loss in 3Q 2024) Third quarter 2025 results: CA$0.001 loss per share (in line with 3Q 2024). Net loss: CA$83.5k (loss widened 1.6% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Board Change • Sep 10
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Aug 13
Genix Pharmaceuticals Corporation announced that it expects to receive CAD 0.1 million in funding Genix Pharmaceuticals Corporation announced that it has entered into a non brokered private placement to issue 2,000,000 units at an issue price of CAD 0.05 for the proceeds of CAD 100,000 on August 11, 2025. Each Unit will be comprised of one common share and one warrant. Each whole warrant will entitle the holder thereof to purchase one common share for a period of 2 years at a price of CAD 0.10. All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance. The transaction is subject to regulatory and stock exchange approval. Certain directors and officers of the company are expected to participate in the Offering. Reported Earnings • Jun 20
First half 2025 earnings released: CA$0.003 loss per share (vs CA$0.002 loss in 1H 2024) First half 2025 results: CA$0.003 loss per share (further deteriorated from CA$0.002 loss in 1H 2024). Net loss: CA$159.2k (loss widened 9.8% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. Board Change • Jun 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • May 15
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Apr 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 01
Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025 Genix Pharmaceuticals Corporation, Annual General Meeting, May 29, 2025. Reported Earnings • Feb 28
Full year 2024 earnings released: CA$0.001 loss per share (vs CA$0.074 loss in FY 2023) Full year 2024 results: CA$0.001 loss per share (improved from CA$0.074 loss in FY 2023). Revenue: CA$4.1k (down 67% from FY 2023). Net loss: CA$73.2k (loss narrowed 98% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings. Board Change • Feb 28
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 22
Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.003 loss in 3Q 2023) Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.003 loss in 3Q 2023). Net loss: CA$82.2k (loss narrowed 50% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 44% per year. Reported Earnings • Jun 28
Second quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 2Q 2023) Second quarter 2024 results: CA$0.001 loss per share (improved from CA$0.004 loss in 2Q 2023). Net loss: CA$85.9k (loss narrowed 63% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Chairman of the Board & President Mahmoud Aziz was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Feb 29
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$1.1m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$221k free cash flow). Shares are highly illiquid. Negative equity (-CA$1.1m). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m (CA$12k revenue, or US$9.1k). Market cap is less than US$10m (CA$2.37m market cap, or US$1.75m). Duyuru • Mar 20
Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021 Genix Pharmaceuticals Corporation, Annual General Meeting, May 19, 2021. Location: Suite 1100-1111 Melville Street Vancouver British Columbia Canada Is New 90 Day High Low • Jan 27
New 90-day high: CA$0.25 The company is up 35% from its price of CA$0.18 on 23 October 2020. The Canadian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 4.0% over the same period. Is New 90 Day High Low • Jan 05
New 90-day high: CA$0.22 The company is up 29% from its price of CA$0.17 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is down 6.0% over the same period. Duyuru • Dec 17
Genix Pharmaceuticals Corporation Announces Executive Changes Genix Pharmaceuticals Corporation announced the appointment of Danny Lee as Chief Financial Officer. Mr. Lee will replace Jamie Lewin as CFO who will remain a director of the Company and will assist in the transition of this role to Mr. Lee. Mr. Lee is a Chartered Professional Accountant with more than 20 years of experience working with public companies in mineral exploration, software, technology and distribution. Mr. Lee's experience includes financial reporting for both Canadian and US listed companies with international operations, corporate finance, strategic planning, tax planning, corporate governance, equity financings and due diligence for acquisitions. Reported Earnings • Sep 30
Third quarter earnings released Over the last 12 months the company has reported total losses of CA$182.3k, with losses widening by 41% from the prior year. Duyuru • Sep 23
Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of Directors Genix Pharmaceuticals Corporation announced that at its annual general meeting held on September 18, 2020, the shareholders elected Darryl Yea to the board of directors. Mr. Yea is currently president of Investco Capital Management Inc. He was formerly chairman, president and chief executive officer of Datawest Solutions Inc. Mr. Yea was a former member of the board of governors of the Vancouver Stock Exchange. Duyuru • Aug 07
Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in funding On August 6, 2020, Genix Pharmaceuticals Corporation (TSXV:GENX) closed the transaction. The company issued 2,571,667 units for proceeds of CAD 385,750 in its second and final tranche. The company received gross proceeds of CAD 1,026,734 in the transaction. The warrant issued will have the expiry date of August 8, 2022, subject to acceleration. In connection with the second and final tranche, the company paid cash commissions of CAD 6,825 and issued 45,500 finders warrants pursuant to and in accordance with applicable securities laws and TSX Venture Exchange policies. The finder’s warrants have the same terms as the Warrants. All securities issued in conjunction with the final tranche closing have a hold period expiring four months and one day following closing. 